Страна: Армения
Език: английски
Източник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
enalapril (enalapril maleate), hydrochlorothiazide
KRKA d.d.
C09BA02
enalapril (enalapril maleate), hydrochlorothiazide
10mg+ 12,5mg
tablets
(20/2x10/) in blister
Prescription
Registered
2022-02-11
PI_Text005185_1 – Updated: Page 1 of 18 1. NAME OF THE MEDICINAL PRODUCT Enap ® -HL 10 mg/12.5 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Enap-HL 10 mg/12.5 mg tablet contains 10 mg enalapril maleate and 12.5 mg hydrochlorothiazide. Excipients: lactose 123.58 mg sodium 1.4 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Round, flat, white, one-side scored tablets with bevelled edges. The score line is not intended for breaking the tablet. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Arterial hypertension (patients for whom the combination therapy is prescribed). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The drug is intended for oral treatment. The dosage of the drug is based primarily on the experience with its active substance enalapril maleate and shall always be individual for each patient. The usual dose is one tablet once daily. If required, the dose may be increase to two tablets once daily. For most patients, 20 mg (exceptionally 40 mg) enalapril maleate or 50 mg hydrochlorothiazide a day is sufficient; therefore, not more than two Enap-HL 10 mg/12.5 mg tablets a day are recommended. If no satisfactory response is achieved, addition of a second drug or changed therapy is recommended (see sections 4.3, 4.4, 4.5 and 5.1). _Prior diuretic therapy_ Symptomatic hypotension may occur following the initial dose of the drug; this is more likely in patients who are volume and/or salt depleted as a result of prior diuretic therapy. The diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with Enap-HL 10 mg/12.5 mg. _Dosage in renal insufficiency_ Thiazide diuretics may not be appropriate for patients with renal impairment. They are ineffective in patients with creatinine clearance values of 0.5 ml/s or less (i.e. moderate and severe renal insufficiency). In patients with creatinine clearance between 0.5 ml/s and 1.3 ml/s, treatment should be started with a suitable dose of individual active substances. CONFIDENTIAL Enap-H 10 Прочетете целия документ